LivaNova is a global medical technology company developing and manufacturing cardiovascular and neuromodulation solutions. The company was founded in 2015 during a merger between Cyberonics and Sorin Group. Headquartered in London, England, LivaNova has a presence in more than 100 countries with a workforce of more than 3,500 employees worldwide. LivaNova is listed on the NASDAQ stock exchange under the ticker symbol “LIVN.”
LivaNova's advanced cardiovascular solutions include the only sutureless valve for aortic surgery and advanced temporary cardiopulmonary support systems that include extracorporeal life support and percutaneous mechanical circulatory support.
LivaNova pioneered the VNS (Vagus Nerve Stimulation) Therapy System and continue to advance medical device solutions for people affected by drug-resistant epilepsy and difficult-to-treat depression. The VNS system is being studied to validate its ability to deliver Autonomic Regulation Therapy for heart failure. Livanova also treats obstructive sleep apnea (OSA) with an implantable device that stimulates multiple tongue muscles via the hypoglossal nerve, opening the airway while a patient is sleeping.
Due to the outbreak of the novel COVID-19 (coronavirus), personal protective equipment and specifically respirators have increased in demand as shortages have occurred in health environments and hospitals. LivaNova looks to remain operational during the pandemic. They continue to supply multiple countries in combating the virus.
Cyberonics And Sorin Group To Merge, Creating A New Premier Global Medical Technology Company